Byannli (previously Paliperidone Janssen-Cilag International) is an antipsychotic medicine used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with injections of paliperidone given every month or every three months.

Byannli contains the active substance paliperidone.

This medicine is similar to Xeplion and Trevicta, which are already authorised in the EU, but are available in different strengths. Scientific data from Xeplion was used during the initial authorisation of Byannli (‘informed consent’).